Sitafloxacin: Difference between revisions
CSV import |
CSV import |
||
| Line 36: | Line 36: | ||
[[Category:Fluoroquinolone antibiotics]] | [[Category:Fluoroquinolone antibiotics]] | ||
[[Category:Antibiotics]] | [[Category:Antibiotics]] | ||
<gallery> | |||
File:Sitafloxacin.svg|Sitafloxacin | |||
</gallery> | |||
Latest revision as of 01:36, 20 February 2025
An article about the antibiotic Sitafloxacin
| Sitafloxacin | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Sitafloxacin is a fluoroquinolone antibiotic used in the treatment of various bacterial infections. It is known for its broad-spectrum activity against both Gram-positive and Gram-negative pathogens.
Mechanism of Action[edit]
Sitafloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes critical for DNA replication and transcription. This inhibition leads to the disruption of bacterial DNA synthesis, ultimately resulting in bacterial cell death.
Pharmacokinetics[edit]
Sitafloxacin is well absorbed after oral administration, with a bioavailability of approximately 90%. It is widely distributed throughout the body, achieving therapeutic concentrations in various tissues and fluids. The drug is primarily excreted via the renal system, with a half-life of approximately 5 to 7 hours.
Clinical Uses[edit]
Sitafloxacin is indicated for the treatment of a variety of infections, including:
- Respiratory tract infections
- Urinary tract infections
- Skin and soft tissue infections
- Gastrointestinal infections
Adverse Effects[edit]
Common adverse effects of sitafloxacin include nausea, diarrhea, and headache. Like other fluoroquinolones, it may also cause more serious side effects such as tendonitis and tendon rupture, particularly in older adults and those on concurrent corticosteroid therapy.
Resistance[edit]
Bacterial resistance to sitafloxacin can occur through mutations in the gyrA and parC genes, which encode the target enzymes DNA gyrase and topoisomerase IV, respectively. Efflux pumps and reduced permeability of the bacterial cell wall can also contribute to resistance.
Related pages[edit]
-
Sitafloxacin